Abstract Details
|
Elisabeth Degenhardt
PRESENTER |
No disclosure on file |
| Michael Witte, PhD (Lilly USA, LLC) | No disclosure on file |
| Michael G. Case, MS (Eli Lilly and Company) | Mr. Case has received personal compensation for serving as an employee of Eli Lilly and Company. Mr. Case has received stock or an ownership interest from Eli Lilly and Company. |
| No disclosure on file | |
| No disclosure on file | |
| Helen Hochstetler, PharmD (Lilly USA) | Helen Hochstetler, PharmD has received personal compensation for serving as an employee of Eli Lilly and Company. Helen Hochstetler, PharmD has received stock or an ownership interest from Eli Lilly and Company. |
| No disclosure on file | |
| Stewart A. Factor, DO, FÂ鶹´«Ã½Ó³» (Emory University School of Medicine) | Dr. Factor has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Neurocrine. Dr. Factor has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dr. Factor has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Takeda. The institution of Dr. Factor has received research support from Biohaven. The institution of Dr. Factor has received research support from Neurocrine. The institution of Dr. Factor has received research support from Supernus. The institution of Dr. Factor has received research support from Sun Pharmaceuticals Advanced Research Company. The institution of Dr. Factor has received research support from Aspen. The institution of Dr. Factor has received research support from RHO. Dr. Factor has received publishing royalties from a publication relating to health care. Dr. Factor has received publishing royalties from a publication relating to health care. Dr. Factor has received publishing royalties from a publication relating to health care. Dr. Factor has received publishing royalties from a publication relating to health care. |
| Paula Trzepacz, MD (Eli Lilly and Company) | No disclosure on file |